Cargando…
The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements
BACKGROUND: Stringent complete response (sCR) is used as a deeper response category than complete response (CR) in multiple myeloma (MM) but may be of limited value in the era of minimal residual disease (MRD) testing. METHODS: Here, we used 4-colour multiparametric flow cytometry (MFC) or next-gene...
Autores principales: | Cedena, Maria-Teresa, Martin-Clavero, Estela, Wong, Sandy, Shah, Nina, Bahri, Natasha, Alonso, Rafael, Barcenas, Carmen, Valeri, Antonio, Salazar Tabares, Johny, Sanchez-Pina, Jose, Cuellar, Clara, Martin, Thomas, Wolf, Jeffrey, Lahuerta, Juan-Jose, Martinez-Lopez, Joaquin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458342/ https://www.ncbi.nlm.nih.gov/pubmed/32866200 http://dx.doi.org/10.1371/journal.pone.0237155 |
Ejemplares similares
-
Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma
por: Leivas, Alejandra, et al.
Publicado: (2016) -
Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma
por: Martinez-Lopez, Joaquin, et al.
Publicado: (2021) -
Measurable residual disease in multiple myeloma: ready for clinical practice?
por: Burgos, Leire, et al.
Publicado: (2020) -
Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
por: Puig, Noemí, et al.
Publicado: (2021) -
Statins surpass SARS
Publicado: (2003)